Fighting Lung Cancer Through the HER Family of Surface Receptors

Buch | Hardcover

340 Seiten

2014
Nova Science Publishers Inc (Verlag)
978-1-63321-092-9 (ISBN)

Artikel merken

Lung cancer is the most common and most lethal malignancy world-wide, causing 1.4 million diseases every year. Half of non-small cell lung cancers (NSCLC) are diagnosed at such an advanced stage that a cure cannot be considered a realistic aim, and over 75% of cases selected for a curative treatment eventually relapse within five years. The 5-year overall survival rates are less than 20% for NSCLC patients. As a disease, NSCLC demands our maximum abilities as researchers, physicians, and care-givers, and a continuous updating of our knowledge. Conventional chemotherapy for advanced NSCLC does not provide a great long-term benefit in terms of survival. Accordingly, a different therapeutic approach has to be explored. The human epidermal growth factor family of surface receptors (HER) became a critical target to be investigated. The epidermal growth factor receptor (EGFR) is over-expressed in over 80% of non-small cell lung cancer. The presence of sensitising conformational mutations in the EGFR increases the efficacy of modern tyrosine kinase inhibitors against its inner portion (EGFR-TKI). The EGFR-TKIs greatly prolong disease-free survival of those patients harbouring sensitising EGFR mutations, and have been suggested as an essential tool in the therapeutic repertoire. This volume aims to serve as an updated compendium of biology and applications of anti-EGFR therapies, and offers a look at the future of anti-HER therapy in lung cancer. This volume exhaustively reviews and discusses: 1) the nature and significance of activating EGFR mutations, and those clinical and pathological phenomena related to HER alterations; 2) the most common laboratory methodologies to study EGFR, and the future of HER analysis; 3) the right time to analyse EGFR mutations and evolutionary changes in the HER; 4) EGFR-TKI application in unselected and selected NSCLC patients; 5) upcoming anti-HER therapies; 6) the eventual role of anti-HER therapies in early NSCLC; 7) mechanisms of acquired resistance to anti-HER therapies, and experimental and conventional strategies to bypass them; 8) the application of anti-HER therapies in other malignancies. This book is an indispensable handbook for all those specialists devoted to the diagnosis and management of lung cancer.

Foreword; Introduction; Lung Cancer I. Epidemiology, Pathology & Diagnosis. Tissue Sampling; Lung Cancer II. Conventional Treatment for Advanced Non-Small Cell Lung Cancer; Biology I. Human Epidermal Growth Factor Receptors in Health & Tumor Cells; Biology II. Etiology & Histology of Lung Cancer According to the Presence of Alterations in the Human Epidermal Growth Factor Family of Receptors; Laboratory I. Analysis of Human Epidermal Growth Factor Receptors: Conventional Analysis; Laboratory II. Experimental Analysis of Human Epidermal Growth Factor Receptors; Timing I. Dynamic Analysis of Human Epidermal Growth Factor Receptors. Role of Rebiopsy; Timing II. Appropriate Time to Determine the Presence of EGFR Mutation & Sequence of Treatment; Treatment I. Treatment of Unselected Patients with Epidermal Growth Factor Tyrosine Kinase Inhibitors; Treatment II. Treatment of Selected Non-Small Cell Lung Cancer Patients; Future I. Still Unapproved Drugs; Future II. Targeted Therapies in Early-Stage Non-Small Cell Lung Cancer; Resistance I. Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer; Resistance II. Conventional Salvage Therapies for the Resistance to Anti-Human Epidermal Growth Factor Receptor Treatments; Other Malignancies I. Breast Cancer; Other Malignancies II. Gynaecological & Head & Neck Cancer; Other Malignancies III. Digestive Tract; Index.

Erscheint lt. Verlag	1.9.2014
Verlagsort	New York
Sprache	englisch
Maße	180 x 260 mm
Gewicht	786 g
Themenwelt	Medizinische Fachgebiete ► Innere Medizin ► Pneumologie
Themenwelt	Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie
ISBN-10	1-63321-092-8 / 1633210928
ISBN-13	978-1-63321-092-9 / 9781633210929
Zustand	Neuware